{"id":942405,"date":"2026-03-05T16:04:48","date_gmt":"2026-03-05T21:04:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/"},"modified":"2026-03-05T16:04:48","modified_gmt":"2026-03-05T21:04:48","slug":"corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/","title":{"rendered":"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026"},"content":{"rendered":"<h2>\nCompany to host conference call and webcast at 4:30 pm ET \/ 1:30 pm PT<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>SOUTH SAN FRANCISCO, Calif., March  05, 2026  (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results.<\/p>\n<p>The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on\u00a0this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d70aM212GA-rPMCg57wlo5O8Ktq5wsrQMhjV1sEIkzr--xyOMboEcMLFPYoy8xR0XpxtqaOFucG1niwqlZ8tnQ==\" rel=\"nofollow\" target=\"_blank\">link<\/a>\u00a0for instant telephone access to the event. The live webcast may be accessed via the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w6yPbZORRznxNeSW0Qf4T48dq8dc0PaOqzCkDWh8ZAow0KT4kD1DbIQecmC9aizTip5_xqarCkX3WlNwqQKMCW6q3FVEj8yqV51ofBzO9J4=\" rel=\"nofollow\" target=\"_blank\">investor relations<\/a> section of the Corvus website. A replay of the webcast will be available on Corvus\u2019 website for 90 days.\u00a0<\/p>\n<p>\n        <strong>About Corvus Pharmaceuticals:<\/strong><br \/>\n        <br \/>Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company\u2019s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed\/refractory PTCL and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t-cuh_jJbRjtbmF_PNG_EqC3NV8B8kX8Y9a4bHncJnXP1QsjmmXr7iKM52vAzlpg7HW1IozZoUXFdHY7xdtwoP3zGcIpi7OfDKJ-5eGYDt8=\" rel=\"nofollow\" target=\"_blank\">www.corvuspharma.com<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ypnJtk-wY7Hm-iV9gQegWgwb6sP3Hfq5B51bYlRmGcxCt0RJ2ncdVtbQyJ0dN4JESC03n3uJBQ6NCk2k9VJTYGFadBKdVMth4tSZb3JbHxoJJSEPjB0cDaS0Xaifwz45\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>INVESTOR CONTACT:\u00a0<br \/>Leiv Lea\u00a0<br \/>Chief Financial Officer\u00a0<br \/>Corvus Pharmaceuticals, Inc.\u00a0<br \/>+1-650-900-4522\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7L2kKRxJfX1wwYEay53MHst9C6u1jF4Bu84gOUqX4MOsC6wNcxS6gSan9yCjDFeJuL-wycDeYV2sgLIbIZYq08ax0_cPjCdlbouLxng2Zn0=\" rel=\"nofollow\" target=\"_blank\">llea@corvuspharma.com<\/a><\/p>\n<p>MEDIA CONTACT:\u00a0<br \/>Sheryl Seapy\u00a0<br \/>Real Chemistry\u00a0<br \/>+1-949-903-4750\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eidA4M1Q4roVwUc7bCJaWs2rNxiCFmuV2M4Y5g5fJ00IcK8VN3DCS_KsrWEd4WOoYfNMen1ZhH7aPdvc26jpQQDq-h2Wv3vExIqf7Nga8GsQ4Jc80BdO10XU66-xltpK\" rel=\"nofollow\" target=\"_blank\">sseapy@realchemistry.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjI1OSM3NDY4NTgwIzIwMjU5OTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmIxNzUxMTAtNjMwNi00NjViLTlkYmYtODM3YjM0ZDhmNzU2LTEwMzc1NjUtMjAyNi0wMy0wNS1lbg==\/tiny\/Corvus-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company to host conference call and webcast at 4:30 pm ET \/ 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on\u00a0this link\u00a0for instant telephone access to the event. The live webcast may be accessed via the\u00a0investor relations section of the Corvus website. A replay of the webcast will be available on Corvus\u2019 website for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942405","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to host conference call and webcast at 4:30 pm ET \/ 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on\u00a0this link\u00a0for instant telephone access to the event. The live webcast may be accessed via the\u00a0investor relations section of the Corvus website. A replay of the webcast will be available on Corvus\u2019 website for &hellip; Continue reading &quot;Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T21:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjI1OSM3NDY4NTgwIzIwMjU5OTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026\",\"datePublished\":\"2026-03-05T21:04:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\\\/\"},\"wordCount\":259,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjI1OSM3NDY4NTgwIzIwMjU5OTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\\\/\",\"name\":\"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjI1OSM3NDY4NTgwIzIwMjU5OTM=\",\"datePublished\":\"2026-03-05T21:04:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjI1OSM3NDY4NTgwIzIwMjU5OTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjI1OSM3NDY4NTgwIzIwMjU5OTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/","og_locale":"en_US","og_type":"article","og_title":"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - Market Newsdesk","og_description":"Company to host conference call and webcast at 4:30 pm ET \/ 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on\u00a0this link\u00a0for instant telephone access to the event. The live webcast may be accessed via the\u00a0investor relations section of the Corvus website. A replay of the webcast will be available on Corvus\u2019 website for &hellip; Continue reading \"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-05T21:04:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjI1OSM3NDY4NTgwIzIwMjU5OTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026","datePublished":"2026-03-05T21:04:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/"},"wordCount":259,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjI1OSM3NDY4NTgwIzIwMjU5OTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/","name":"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjI1OSM3NDY4NTgwIzIwMjU5OTM=","datePublished":"2026-03-05T21:04:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjI1OSM3NDY4NTgwIzIwMjU5OTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjI1OSM3NDY4NTgwIzIwMjU5OTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942405"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942405\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}